Bloudek, Lisa
Eichenfield, Lawrence F.
Silverberg, Jonathan I.
Joish, Vijay N.
Lofland, Jennifer H.
Sun, Kang
Augustin, Matthias
Migliaccio-Walle, Kristen
Sullivan, Sean D.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
https://doi.org/10.1007/s40257-021-00610-x
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
https://doi.org/10.1007/s40257-022-00734-8
Documents that mention this clinical trial
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
https://doi.org/10.1007/s40257-021-00610-x
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
https://doi.org/10.1007/s40257-022-00734-8
Funding for this research was provided by:
Incyte
Article History
Accepted: 28 September 2022
First Online: 20 October 2022
Declarations
:
: The study was funded by Incyte Corporation (Wilmington, DE, USA).
: Lisa Bloudek, Kristen Migliaccio-Walle, and Sean D. Sullivan are employees of Curta Inc. and served as paid consultants to Incyte Corporation in connection with this study. Lawrence F. Eichenfield has served as an investigator, consultant, speaker, or data safety monitoring board member for AbbVie, Almirall, Arcutis, Asana BioSciences, Dermavant, Eli Lilly, Forte Biosciences, Galderma, Ichnos/Glenmark, Incyte Corporation, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Otsuka, Pfizer, Regeneron, and Sanofi Genzyme. Jonathan I. Silverberg has received honoraria for advisory board, speaker, and consultant services from AbbVie, Asana, Bluefin, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Incyte Corporation, Kiniksa, LEO Pharma, Menlo, Novartis, Pfizer, Realm, Regeneron, and Sanofi; and research grants for investigator services from GlaxoSmithKline and Galderma. Vijay N. Joish, Jennifer H. Lofland, and Kang Sun are employees and shareholders of Incyte Corporation. Matthias Augustin has served as a consultant, researcher, and/or has received research grants from AbbVie, ALK-AbellĂł, Almirall, Amgen, Bayer, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Dermira, Eli Lilly, Galderma, Genzyme, GlaxoSmithKline, Hexal, Janssen, LEO Pharma, Medac, Menlo Therapeutics, MSD, Mylan B.V., Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Stallergenes, Trevi, and XenoPort. Sean D. Sullivan is an owner of VeriTech Corporation and served as a consultant to Incyte Corporation in connection with this study.
: The study was conducted in accordance with the International Council on Harmonisation Guideline for Good Clinical Practice, the Declaration of Helsinki, and all other applicable local ethical and legal requirements.
: Written informed consent or assent was provided by all patients before enrollment.
: Not applicable.
: Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte Corporation for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except phase I studies) for which the product and indication were approved on or after 1 January, 2020 in at least one major market (e.g., USA, European Union, Japan). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte Corporation’s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at: ExternalRef removed.
: Not applicable.
: All authors contributed to the study conception and design and development of the manuscript. All authors read and approved the final manuscript.